Author + information
- Received June 13, 2006
- Revision received August 17, 2006
- Accepted August 21, 2006
- Published online January 2, 2007.
- Pascal Meier, MD,
- Rainer Zbinden, MD,
- Mario Togni, MD,
- Peter Wenaweser, MD,
- Stephan Windecker, MD,
- Bernhard Meier, MD, FACC, FESC and
- Christian Seiler, MD, FACC, FESC⁎ ()
- ↵⁎Reprint requests and correspondence:
Dr. Christian Seiler, Professor and Co-Chairman of Cardiology, University Hospital, CH-3010 Bern, Switzerland.
Objectives This study was designed to compare coronary collateral function in patients after bare-metal stent (BMS) or drug-eluting stent (DES) implantation.
Background Drug-eluting stents have an inhibitory effect on the production of cytokines, chemotactic proteins, and growth factors, and may therefore negatively affect coronary collateral growth.
Methods A total of 120 patients with long-term stable coronary artery disease (CAD) after stent implantation were included. Both the BMS group and the DES group comprised 60 patients matched for in-stent stenosis severity of the vessel undergoing collateral flow index (CFI) measurement at follow-up and for the duration of follow-up. The primary end point of the investigation was invasively determined coronary collateral function 6 months after stent implantation. Collateral function was assessed by simultaneous aortic, coronary wedge, and central venous pressure measurements (yielding CFI) and by intracoronary electrocardiogram during balloon occlusion.
Results There were no differences between the groups regarding age, gender, body mass index, frequency of cardiovascular risk factors, use of cardiovascular drugs, severity of CAD, or site of coronary artery stenoses. Despite equal in-stent stenosis severity (46 ± 34% and 45 ± 36%) and equal follow-up duration (6.2 ± 10 months and 6.5 ± 5.4 months), CFI was diminished in the DES versus BMS group (0.154 ± 0.097 vs. 0.224 ± 0.142; p = 0.0049), and the rate of collaterals insufficient to prevent ischemia during occlusion (intracoronary electrocardiographic ST-segment elevation ≥0.1 mV) was higher with 50 of 60 patients in the DES group and 33 of 60 patients in the BMS group (p = 0.001).
Conclusions Collateral function long after coronary stenting is impaired with DES (sirolimus and paclitaxel) when compared with BMS. Considering the protective nature of collateral vessels, this could lead to more serious cardiac events in the presence of an abrupt coronary occlusion.
Supported by a grant from the Swiss National Science Foundation, #3200BO-100065/1.
- Received June 13, 2006.
- Revision received August 17, 2006.
- Accepted August 21, 2006.
- American College of Cardiology Foundation